Eliquis (apixaban) Mechanism of Action
An oral, direct and highly selective factor Xa inhibitor1
ELIQUIS inhibits free and clot-bound factor Xa, and prothrombinase activity.
ELIQUIS has no direct effects on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting factor Xa, ELIQUIS prevents thrombin generation and thrombus development.1
- Factor Xa is the primary site of amplification in the coagulation cascade2
- ELIQUIS binds reversibly to Factor Xa1
- One factor Xa molecule leads to the formation of ~1,000 thrombin molecules2
Adapted from Eriksson et al. 2011.3
Please click here to access the ELIQUIS Patient Information Leaflet.
DVT = Deep Vein Thrombosis
NVAF = Non-Valvular Atrial Fibrillation
PE = Pulmonary Embolism
TF = Tissue Factor
References
- ELIQUIS® (apixaban) Summary of Product Characteristics.
- Turpie AGG. Arterioscler Thromb Vasc Biol 2007; 27: 1238–1247.
- Eriksson BI et al. Annu Rev Med 2011; 62: 41–57.